Dec 9, 2019
SANTA MONICA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVID) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that its first batch of BIV201 prefilled syringes containing a patent-pending formula...
Oct 22, 2019
SANTA MONICA, CA / ACCESSWIRE / October 22, 2019 / BioVie Inc. (OTCQB:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has submitted for assessment by the U.S. Food and Drug Administration ("FDA") the Phase 2b...
Apr 30, 2019
LOS ANGELES, April 30, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) ...